Coverage changes for Remicade and biosimilars

We want to make you aware of some upcoming coverage changes related to the monoclonal antibody medication Remicade (infliximab) and its biosimilars. Effective Jan. 1, 2026, Avsola and Inflectra will be the preferred infliximab products. Remicade and unbranded Infliximab (HCPCS code J1745) will become non-preferred products.

This coverage change will apply to members initiating treatment of infliximab on or after Jan. 1. Our Medical Benefit Drug MNG for Targeted Immunomodulators – Skilled Administration and Medicare Part B Step Therapy have been updated to reflect these changes.